Aligos Therapeutics, Inc. Comprehensive Income
Aligos Therapeutics, Inc. (ALGS) reported Comprehensive Income of -$1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$1.50M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$23.07M, a 153.55% decline year-over-year.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$19.87M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$31.50M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$24.18M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$131.31M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$87.53M.
- Aligos Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$96.10M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.50M 10-Q · filed 2026-08-06 | -$24.57M 10-Q · filed 2026-08-06 | -$44.44M derived: sum of 3 quarters · filed 2026-08-06 | -$75.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$23.07M 10-Q · filed 2026-05-07 | -$42.94M derived: sum of 2 quarters · filed 2026-05-07 | -$74.44M derived: sum of 3 quarters · filed 2026-05-07 | -$90.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$19.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$51.37M derived: sum of 2 quarters · filed 2026-03-05 | -$67.26M derived: sum of 3 quarters · filed 2026-08-06 | -$24.18M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$31.50M 10-Q · filed 2025-11-06 | -$47.39M derived: sum of 2 quarters · filed 2026-08-06 | -$4.31M 10-Q · filed 2025-11-06 | -$86.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.89M 10-Q · filed 2026-08-06 | $27.19M 10-Q · filed 2026-08-06 | -$55.08M derived: sum of 3 quarters · filed 2026-08-06 | -$74.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.08M 10-Q · filed 2026-05-07 | -$39.19M derived: sum of 2 quarters · filed 2026-05-07 | -$58.37M derived: sum of 3 quarters · filed 2026-05-07 | -$53.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$82.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$101.45M derived: sum of 2 quarters · filed 2026-03-05 | -$96.37M derived: sum of 3 quarters · filed 2026-03-05 | -$131.31M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$19.18M 10-Q · filed 2025-11-06 | -$14.10M derived: sum of 2 quarters · filed 2025-11-06 | -$49.03M 10-Q · filed 2025-11-06 | -$76.87M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.08M 10-Q · filed 2025-08-06 | -$29.85M 10-Q · filed 2025-08-06 | -$57.70M derived: sum of 3 quarters · filed 2025-08-06 | -$75.74M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$34.93M 10-Q · filed 2025-05-06 | -$62.78M derived: sum of 2 quarters · filed 2025-05-06 | -$80.82M derived: sum of 3 quarters · filed 2025-05-06 | -$99.61M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$27.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$45.88M derived: sum of 2 quarters · filed 2025-03-10 | -$64.68M derived: sum of 3 quarters · filed 2025-03-10 | -$87.53M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$18.04M 10-Q · filed 2024-11-06 | -$36.83M derived: sum of 2 quarters · filed 2024-11-06 | -$59.69M 10-Q · filed 2024-11-06 | -$81.33M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$18.79M 10-Q · filed 2024-08-06 | -$41.65M 10-Q · filed 2024-08-06 | -$63.29M derived: sum of 3 quarters · filed 2024-08-06 | -$81.81M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$22.86M 10-Q · filed 2024-05-07 | -$44.50M derived: sum of 2 quarters · filed 2024-05-07 | -$63.01M derived: sum of 3 quarters · filed 2024-05-07 | -$83.09M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$21.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$40.16M derived: sum of 2 quarters · filed 2024-03-12 | -$60.23M derived: sum of 3 quarters · filed 2024-03-12 | -$96.10M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$18.51M 10-Q · filed 2023-11-02 | -$38.59M derived: sum of 2 quarters · filed 2023-11-02 | -$74.45M 10-Q · filed 2023-11-02 | -$111.47M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$20.08M 10-Q · filed 2023-08-03 | -$55.94M 10-Q · filed 2023-08-03 | -$92.95M derived: sum of 3 quarters · filed 2023-08-03 | -$126.08M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$35.86M 10-Q · filed 2023-05-04 | -$72.88M derived: sum of 2 quarters · filed 2023-05-04 | -$106.00M derived: sum of 3 quarters · filed 2023-05-04 | -$135.84M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$37.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$70.14M derived: sum of 2 quarters · filed 2023-03-09 | -$99.98M derived: sum of 3 quarters · filed 2023-03-09 | -$127.69M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$33.12M 10-Q · filed 2022-11-02 | -$62.97M derived: sum of 2 quarters · filed 2022-11-02 | -$90.68M 10-Q · filed 2022-11-02 | -$125.32M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$29.84M 10-Q · filed 2022-08-04 | -$57.55M 10-Q · filed 2022-08-04 | -$92.19M derived: sum of 3 quarters · filed 2022-08-04 | -$125.61M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$27.71M 10-Q · filed 2022-05-04 | -$62.35M derived: sum of 2 quarters · filed 2022-05-04 | -$95.77M derived: sum of 3 quarters · filed 2022-05-04 | -$116.87M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$34.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$68.06M derived: sum of 2 quarters · filed 2022-03-10 | -$89.15M derived: sum of 3 quarters · filed 2022-03-10 | -$108.62M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$33.41M 10-Q · filed 2021-11-04 | -$54.51M derived: sum of 2 quarters · filed 2021-11-04 | -$73.98M 10-Q · filed 2021-11-04 | -$92.19M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$21.10M 10-Q · filed 2021-08-05 | -$40.56M 10-Q · filed 2021-08-05 | -$58.78M derived: sum of 3 quarters · filed 2021-08-05 | -$72.87M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$19.46M 10-Q · filed 2021-05-10 | -$37.68M derived: sum of 2 quarters · filed 2021-05-10 | -$51.77M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$18.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$32.31M derived: sum of 2 quarters · filed 2021-03-23 | -$52.38M 10-K · filed 2021-03-23 | |
| 2019-09-30 | -$14.09M 10-Q · filed 2020-11-25 | -$34.16M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |